ipilimumab,nivolumab,canakinumab
bms,Novartis
['nsclc', 'sclc', 'increase,(-increased)']
the difference here is radiation and in t3/t4 nsclc, local control is so critical. largely unexplored to date. the increase study explores quad-modality therapy and the results were quite impressive. high pcr rates and seen across pdl1 strata, not just in pdl1 high. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him